MapLight Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed August 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Catalyst4, Inc. filed a Schedule 13D/A (amended statement of beneficial ownership) regarding MapLight Therapeutics, Inc. on August 18, 2026. The filing document itself contains no substantive disclosure of specific share counts, dollar amounts, percentages, or details of what changed in the ownership position. Without access to the full document content, the material facts of this amendment cannot be specified.
Why this rating
Routine amended disclosure filing; no material facts disclosed in header/metadata. Cannot assess without document substance.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.